UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003609
Receipt number R000004331
Scientific Title The effects of selective alpha-1-adrenergic receptor antagonists in patients with lower urinary tract symptoms caused by benign prostatic hyperplasiawho failed to obtain sufficient efficacy by previous alpha-1-blockades. . A comparison of Naftopidil or Silodosin.
Date of disclosure of the study information 2010/05/16
Last modified on 2010/05/12 07:32:24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effects of selective alpha-1-adrenergic receptor antagonists in patients with lower urinary tract symptoms caused by benign prostatic hyperplasiawho failed to obtain sufficient efficacy by previous alpha-1-blockades.
. A comparison of Naftopidil or Silodosin.

Acronym

The effects of selective alpha-1- adrenergic receptor antagonists in patients with lower urinary tract symptoms caused by benign prostatic hyperplasia. A comparison of Naftopidil or Silodosin.

Scientific Title

The effects of selective alpha-1-adrenergic receptor antagonists in patients with lower urinary tract symptoms caused by benign prostatic hyperplasiawho failed to obtain sufficient efficacy by previous alpha-1-blockades.
. A comparison of Naftopidil or Silodosin.

Scientific Title:Acronym

The effects of selective alpha-1- adrenergic receptor antagonists in patients with lower urinary tract symptoms caused by benign prostatic hyperplasia. A comparison of Naftopidil or Silodosin.

Region

Japan


Condition

Condition

Benign Prostatic Hyperplasia

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To study the safety and efficacy of selective alpha 1 adrenergic receptor antagonists in patients with lower urinary tract symptoms caused by benign prostatic hyperplasia who failed to obtain sufficient efficacy by previous alpha-blockades.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

IPSS score QOL score Blood pressure

Key secondary outcomes

Uroflowmetry


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

We assess the clinical efficacy and safety of the loading dosage escalation to naftopidil 75mg in patients with lower urinary tract symptoms caused by benign prostatic hyperplasia who failed to obtain sufficient efficacy by naftopidil 50mg.

Interventions/Control_2

We assess the clinical efficacy and safety of switchover treatment with silodosin 8mg in patients with lower urinary tract symptoms caused by benign prostatic hyperplasia who failed to obtain sufficient efficacy by naftopidil 50mg.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

Men with lower urinary tract symptoms caused by benign prostatic hyperplasia who failed to obtain sufficient efficacy by naftopidil 50mg and with International Prostate Symptom Score(IPSS) of>=9,a quality-of-life (QOL)score of >=2,a prostate volume of>=20ml are eligible for enrolment.

Key exclusion criteria

none

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shigenari Kawakita

Organization

kansai Medical University Takii Hospital

Division name

Department of Urology

Zip code


Address

10-15 Fumizono, Moriguchi, Osaka, Japan

TEL

06-6992-1001

Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Kansai Medical University Takii Hospital

Division name

Deaprtment of Urology

Zip code


Address


TEL


Homepage URL


Email



Sponsor or person

Institute

Kansai Medical University Takii Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

関西医科大学附属滝井病院


Other administrative information

Date of disclosure of the study information

2010 Year 05 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2010 Year 03 Month 16 Day

Date of IRB


Anticipated trial start date

2010 Year 05 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 05 Month 13 Day

Last modified on

2010 Year 05 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004331


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name